10x Genomics (NASDAQ:TXG) Earns “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG) in a research report report published on Thursday morning,Weiss Ratings reports.

Several other brokerages also recently weighed in on TXG. Stifel Nicolaus reduced their target price on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. JPMorgan Chase & Co. reduced their price objective on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Canaccord Genuity Group decreased their price objective on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Leerink Partnrs cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 13th. Finally, Citigroup decreased their price target on 10x Genomics from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $19.79.

10x Genomics Trading Up 3.6 %

Shares of NASDAQ:TXG opened at $8.31 on Thursday. The company has a 50-day moving average price of $9.55 and a 200 day moving average price of $13.19. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $29.37. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -5.47 and a beta of 2.01.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, equities analysts forecast that 10x Genomics will post -1.43 EPS for the current year.

Insider Buying and Selling

In other news, insider Benjamin J. Hindson sold 4,573 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the transaction, the insider now directly owns 335,324 shares of the company’s stock, valued at approximately $3,712,036.68. The trade was a 1.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Alan Mateo acquired 40,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were bought at an average price of $11.14 per share, with a total value of $445,600.00. Following the completion of the purchase, the director now directly owns 61,691 shares in the company, valued at $687,237.74. The trade was a 184.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 10.03% of the stock is owned by insiders.

Hedge Funds Weigh In On 10x Genomics

A number of large investors have recently added to or reduced their stakes in TXG. Signaturefd LLC grew its position in shares of 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after buying an additional 1,452 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in 10x Genomics in the fourth quarter valued at approximately $32,000. Blue Trust Inc. grew its holdings in 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock worth $44,000 after purchasing an additional 1,299 shares during the last quarter. Sound Income Strategies LLC increased its position in shares of 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after purchasing an additional 1,330 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of 10x Genomics during the fourth quarter worth $52,000. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.